Healwell AI's earnings call reflects a strong growth trajectory fueled by strategic acquisitions and expansion in AI and data science segments. Despite facing challenges such as increased net loss and adjusted EBITDA loss, the company has made significant progress in revenue growth and strategic partnerships. The impact of external factors like the Inflation Reduction Act poses challenges, but the company remains optimistic about future growth and profitability.

Company Guidance

During the Q3 2024 earnings call for Healwell AI, the company provided a comprehensive overview of its financial and strategic progress. Key financial metrics included a significant increase in quarterly revenue to CAD 13.7 million from CAD 1.6 million the previous year, primarily driven by strategic acquisitions. Adjusted gross profit rose to CAD 5.9 million, with a gross margin of 43%, up from 20% in Q3 2023. However, the company reported an adjusted EBITDA loss of CAD 3.4 million and a net loss of CAD 11.1 million. The call highlighted the company's impressive growth trajectory, with annualized revenue run rate increasing eightfold to CAD 58.4 million. Strategic acquisitions, such as VeroSource Solutions and BioPharma Services, were noted as transformational, enhancing Healwell's financial profile and capabilities. The company anticipates reaching a CAD 100 million revenue run rate and profitability on an adjusted EBITDA basis in the near future. Healwell also emphasized its expansion in AI solutions and clinical research, with 27 signed master service agreements with life sciences partners, including seven of the top ten largest pharmaceutical companies.

Significant Revenue Growth

Healwell achieved quarterly revenues of $13.7 million in Q3 2024, compared to $1.6 million in the same quarter last year, driven by recent acquisitions.

AI and Data Science Segment Expansion

The AI and data science segment experienced an impressive 2,800% revenue growth this quarter as compared to the same quarter of 2023.

Increase in Master Service Agreements

Healwell's AI and data science subsidiaries executed 5 new MSAs in Q3 2024, bringing the cumulative total to 27, including partnerships with 7 of the top 10 largest pharmaceutical companies.

Strategic Acquisitions and Expansion

Acquired VeroSource Solutions and BioPharma Services, enhancing clinical research capabilities and financial profile. Expanded clinical research services for the pharmaceutical industry.

Prix Galien USA 2024 Award

Pentavere received the prestigious Prix Galien USA 2024 Award for Best Digital Health start-up in AI for life sciences.

---

MCI Onehealth Technologies, Inc. Class A (TSE:AIDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:AIDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 30, 2021	2020 (Q4)	- / -0.04	0.003	-1600.00% (-0.05)	―	―
May 13, 2021	2021 (Q1)	-0.04 / -0.05	-0.007	-614.29% (-0.04)	―	―
Aug 16, 2021	2021 (Q2)	-0.04 / -0.06	0.01	-700.00% (-0.07)	―	―
Nov 15, 2021	2021 (Q3)	-0.06 / -0.11	0.02	-650.00% (-0.13)	―	―
Mar 31, 2022	2021 (Q4)	-0.09 / -0.09	-0.05	-80.00% (-0.04)	―	―
May 16, 2022	2022 (Q1)	- / -	-0.05	―	―	―
Aug 15, 2022	2022 (Q2)	-0.07 / -0.08	-0.06	-33.33% (-0.02)	―	―
Nov 14, 2022	2022 (Q3)	-0.08 / -0.18	-0.11	-63.64% (-0.07)	―	―
Apr 01, 2023	2022 (Q4)	-0.05 / -0.15	-0.09	-66.67% (-0.06)	―	―
May 16, 2023	2023 (Q1)	- / -	-0.09	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

TSE:AIDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2024	C$1.77	C$1.81	+2.26%
Aug 12, 2024	C$2.06	C$2.00	-2.91%
May 14, 2024	C$1.50	C$1.50	0.00%
Nov 15, 2023	C$0.82	C$0.85	+3.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---

FAQ

When does MCI Onehealth Technologies, Inc. Class A (TSE:AIDX) report earnings?

MCI Onehealth Technologies, Inc. Class A (TSE:AIDX) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.

What is MCI Onehealth Technologies, Inc. Class A (TSE:AIDX) earnings time?

MCI Onehealth Technologies, Inc. Class A (TSE:AIDX) earnings time is at Mar 27, 2025, TBA Not Confirmed.

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:AIDX EPS forecast?

TSE:AIDX EPS forecast for the fiscal quarter 2024 (Q4) is -0.03.

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing